MEMPHIS, Tenn., January 07, 2025--(BUSINESS WIRE)--FedEx Corp. (NYSE: FDX) ("FedEx") announced today the commencement of offers to exchange any and all of its outstanding senior notes of the ...
Also Read: Big Biopharma Trails Behind The Market: JP Morgan’s 2025 Outlook on Eli Lilly, Merck, and More In March 2024, the FDA approved Winrevair (sotatercept-csrk), for injection, 45mg ...
On December 19, 2024, FedEx Corp. (NYSE: FDX, $278.66, Market Capitalization: $67.1 billion) announced that its Board of Directors had concluded a comprehensive assessment of the role of FedEx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback